Seven‐year safety and efficacy with velaglucerase alfa for treatment‐naïve adult patients with type 1 Gaucher disease

E-ISSN： 1096-8652|90|7|577-583

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.7, 2015-07, pp. : 577-583

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : 592-597

John Wiley & Sons Inc

Access to resources Recommend Favorite

Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long‐term data from phase III clinical trials

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : 584-591

John Wiley & Sons Inc

Access to resources Recommend Favorite

Relative efficacy and safety of simeprevir and telaprevir in treatment‐naïve hepatitis C‐infected patients in a Japanese population: A Bayesian network meta‐analysis

HEPATOLOGY RESEARCH, Vol. 45, Iss. 10, 2015-10 ,pp. : E89-E98

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

By Rosenstock J. Aguilar-Salinas C. Klein E. Nepal S. List J. Chen R.

Current Medical Research and Opinion, Vol. 25, Iss. 10, 2009-10 ,pp. : 2401-2411

Informa Healthcare

Access to resources Recommend Favorite

Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents*

By Silver M. R. Geronemus R. Krause M. Chen C. Y. Kewalramani R. Stehman-Breen C.

Current Medical Research and Opinion, Vol. 25, Iss. 1, 2009-01 ,pp. : 123-131

Informa Healthcare

Access to resources Recommend Favorite